Reslizumab (Sch 55700) 是靶向人白介素 5 (IL-5) 的人源化单克隆抗体，用于治疗嗜酸性粒细胞性哮喘。Reslizumab 可有效阻断 IL-5 的功能。Reslizumab 抑制 IL-5 依赖性细胞增殖，IC50 值约为 91.1pM。Reslizumab 对人 IL-5 具有高结合亲和力，在 Biacore 表面等离振子共振和动力学排斥分析中，KD 值分别为 109 pM 和 4.3 pM。
货号:ajcx16618
CAS:241473-69-8
分子式:N/A
分子量：N/A
溶解度:Soluble in DMSO
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91.1pM. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[1][2].

[1]. Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298. [2]. PÉrez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4.